CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...